Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer

A Korean gynecologic oncology group study (OV 1708)

Young Shin Chung, Sang Yoon Park, Jung Yun Lee, Jeong Yeol Park, Jeong Won Lee, Hee Seung Kim, Dong Soo Suh, Yun Hwan Kim, Jong Min Lee, Miseon Kim, Min Chul Choi, Seung Hyuk Shim, Keun Ho Lee, Taejong Song, Jin-Hwa Hong, Won Moo Lee, Banghyun Lee, In Ho Lee

Research output: Contribution to journalArticle

Abstract

Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results: A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma, 31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease ≤1 cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for performing NAC was high tumor burden (n = 106, 68.8%). The median progression-free survival (PFS) was 14.3 months and median overall survival (OS) was 52.9 months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p = 0.007 and p = 0.017, respectively) and OS (p = 0.002 and p = 0.013, respectively). Conclusions: In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.

Original languageEnglish
Article number341
JournalBMC Cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 Apr 11

Fingerprint

Ovarian Neoplasms
Carcinoma
Drug Therapy
Survival
Disease-Free Survival
Endometrioid Carcinoma
Carcinosarcoma
Mucinous Adenocarcinoma
Tumor Burden
Cohort Studies
Multivariate Analysis
Survival Rate
Retrospective Studies
Demography

Keywords

  • Histologic subtype
  • Neoadjuvant therapy
  • Non-high grade serous carcinoma
  • Ovarian neoplasms
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer : A Korean gynecologic oncology group study (OV 1708). / Chung, Young Shin; Park, Sang Yoon; Lee, Jung Yun; Park, Jeong Yeol; Lee, Jeong Won; Kim, Hee Seung; Suh, Dong Soo; Kim, Yun Hwan; Lee, Jong Min; Kim, Miseon; Choi, Min Chul; Shim, Seung Hyuk; Lee, Keun Ho; Song, Taejong; Hong, Jin-Hwa; Lee, Won Moo; Lee, Banghyun; Lee, In Ho.

In: BMC Cancer, Vol. 19, No. 1, 341, 11.04.2019.

Research output: Contribution to journalArticle

Chung, YS, Park, SY, Lee, JY, Park, JY, Lee, JW, Kim, HS, Suh, DS, Kim, YH, Lee, JM, Kim, M, Choi, MC, Shim, SH, Lee, KH, Song, T, Hong, J-H, Lee, WM, Lee, B & Lee, IH 2019, 'Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: A Korean gynecologic oncology group study (OV 1708)', BMC Cancer, vol. 19, no. 1, 341. https://doi.org/10.1186/s12885-019-5514-7
Chung, Young Shin ; Park, Sang Yoon ; Lee, Jung Yun ; Park, Jeong Yeol ; Lee, Jeong Won ; Kim, Hee Seung ; Suh, Dong Soo ; Kim, Yun Hwan ; Lee, Jong Min ; Kim, Miseon ; Choi, Min Chul ; Shim, Seung Hyuk ; Lee, Keun Ho ; Song, Taejong ; Hong, Jin-Hwa ; Lee, Won Moo ; Lee, Banghyun ; Lee, In Ho. / Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer : A Korean gynecologic oncology group study (OV 1708). In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{c404a6e7d29046c5bb18c9f97815811f,
title = "Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: A Korean gynecologic oncology group study (OV 1708)",
abstract = "Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results: A total of 154 patients were included in this study, comprising 20 cases (13.0{\%}) of mucinous adenocarcinoma, 31 cases (20.1{\%}) of endometrioid adenocarcinoma, 28 (18.2{\%}) cases of clear cell carcinoma, 29 (18.8{\%}) cases of low-grade serous carcinoma and 12 cases (7.8{\%}) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9{\%}) patients and optimal debulking surgery (residual disease ≤1 cm) at interval debulking surgery was achieved in 103 (66.9{\%}) patients. The most common reason for performing NAC was high tumor burden (n = 106, 68.8{\%}). The median progression-free survival (PFS) was 14.3 months and median overall survival (OS) was 52.9 months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p = 0.007 and p = 0.017, respectively) and OS (p = 0.002 and p = 0.013, respectively). Conclusions: In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.",
keywords = "Histologic subtype, Neoadjuvant therapy, Non-high grade serous carcinoma, Ovarian neoplasms, Survival",
author = "Chung, {Young Shin} and Park, {Sang Yoon} and Lee, {Jung Yun} and Park, {Jeong Yeol} and Lee, {Jeong Won} and Kim, {Hee Seung} and Suh, {Dong Soo} and Kim, {Yun Hwan} and Lee, {Jong Min} and Miseon Kim and Choi, {Min Chul} and Shim, {Seung Hyuk} and Lee, {Keun Ho} and Taejong Song and Jin-Hwa Hong and Lee, {Won Moo} and Banghyun Lee and Lee, {In Ho}",
year = "2019",
month = "4",
day = "11",
doi = "10.1186/s12885-019-5514-7",
language = "English",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer

T2 - A Korean gynecologic oncology group study (OV 1708)

AU - Chung, Young Shin

AU - Park, Sang Yoon

AU - Lee, Jung Yun

AU - Park, Jeong Yeol

AU - Lee, Jeong Won

AU - Kim, Hee Seung

AU - Suh, Dong Soo

AU - Kim, Yun Hwan

AU - Lee, Jong Min

AU - Kim, Miseon

AU - Choi, Min Chul

AU - Shim, Seung Hyuk

AU - Lee, Keun Ho

AU - Song, Taejong

AU - Hong, Jin-Hwa

AU - Lee, Won Moo

AU - Lee, Banghyun

AU - Lee, In Ho

PY - 2019/4/11

Y1 - 2019/4/11

N2 - Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results: A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma, 31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease ≤1 cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for performing NAC was high tumor burden (n = 106, 68.8%). The median progression-free survival (PFS) was 14.3 months and median overall survival (OS) was 52.9 months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p = 0.007 and p = 0.017, respectively) and OS (p = 0.002 and p = 0.013, respectively). Conclusions: In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.

AB - Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results: A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma, 31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease ≤1 cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for performing NAC was high tumor burden (n = 106, 68.8%). The median progression-free survival (PFS) was 14.3 months and median overall survival (OS) was 52.9 months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p = 0.007 and p = 0.017, respectively) and OS (p = 0.002 and p = 0.013, respectively). Conclusions: In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.

KW - Histologic subtype

KW - Neoadjuvant therapy

KW - Non-high grade serous carcinoma

KW - Ovarian neoplasms

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85064200183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064200183&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-5514-7

DO - 10.1186/s12885-019-5514-7

M3 - Article

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 341

ER -